Evidence map›Paper›PMID 36334390›Full record

Trial reportPhytomedicine : international journal of phytotherapy and phytopharmacology2023

Efficacy and safety of Reyanning mixture in patients infected with SARS-CoV-2 Omicron variant: A prospective, open-label, randomized controlled trial.

Xiangru Xu, Shuang Zhou, Caiyu Chen, Jinhua Li, Hongze Wu, Guoqiang Jin, Jing Zhou, Gang Wang, Min Cao, Ding Sun and 6 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Effects of Bairui granules (Frontiers in pharmacology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Xiangru XuDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shuang ZhouAcupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Caiyu ChenDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jinhua LiJiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, China.
Hongze WuJiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, China.
Guoqiang JinDepartment of Health Management, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Jing ZhouDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Gang WangDepartment of Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Min CaoDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ding SunDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wen ZhangDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wei PengDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuting PuDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuting SunDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Bangjiang FangDepartment of Emergency, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: fangbji@163.com.
Jianguang XuSchool of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: jianguangxu@fudan.edu.cn.
Longhua Hospital Shanghai University of Traditional Chinese Medicine · CNShanghai University of Traditional Chinese Medicine · CNFirst Affiliated Hospital of Nanchang University · CNJiujiang Maternal and Child Care Centres · CNSecond Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant rapidly resulted in a steep increase in the infected population and an overloaded healthcare system. Effective medications for Omicron are currently limited. The previous observational study supports the efficacy and safety of Reyanning (RYN) mixture in the treatment of coronavirus disease 2019 (COVID-19). PURPOSE: To evaluate the efficacy of RYN in asymptomatic and mildly infected patients with SARS-CoV-2 infection. STUDY DESIGN AND

methodsThis study was a prospective, open-label, randomized controlled trial. We consecutively recruited 2830 patients from Shanghai New International Expo Center mobile cabin hospital and randomized them in a 1:1 ratio to receive RYN plus standard care or receive standard care alone. The primary outcomes were the negative conversion of nucleic acid. Secondary outcomes included the hospital duration, new-onset symptoms, proportion of disease progression, and the viral load measured by the cycle threshold (Ct) value.

resultsA total of 1393 patients in the intervention group and 1407 patients in the control group completed the study. The negative conversion time of nucleic acid was significantly shortened in the intervention group (median: 6 d vs. 7 d, Hazard ratio: 0.768, 95CI %: 0.713-0.828, p < 0.0001). The negative conversion rate of nucleic acid was significantly higher in the intervention group (Day 3: 32.4% vs. 18.3%; Day7: 65.3% vs. 55.2%, p < 0.001). The hospitalization duration was significantly shortened in the intervention group (median: 8 d vs. 9 d, Hazard ratio: 0.759, 95% CI: 0.704-0.818, p < 0.0001). The proportion of new-onset fever (2.4% vs. 4.1%, p = 0.012), coughing (12.2% vs. 14.8%, p = 0.046), and expectoration (6.0% vs. 8.0%, p = 0.032) in the intervention group was significantly lower. RYN treatment increased Ct values and reduced the viral load. No disease progression and serious adverse events were reported during the study.

conclusionRYN is a safe and effective treatment that can accelerate virus clearance and promote disease recovery in asymptomatic and mild Omicron infections.

Indexed as

COVID-19 Drug TreatmentNucleic AcidsChinaHumansProspective StudiesSARS-CoV-2Treatment OutcomeNucleic AcidsCoronavirus disease 2019OmicronRandomized controlled trialReyanning mixtureSevere acute respiratory syndrome coronavirus 2Traditional Chinese medicine

Identifiers

PMID36334390
PMCPMC9616513
OpenAlexW4308152357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.